Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
Dena P. Rhinehart, Jiaying Lai, David E. Sanin, Varsha Vakkala, Adrianna Mendes, Christopher Bailey, Emmanuel S. Antonarakis, Channing J. Paller, Xiaojun Wu, Tamara L. Lotan, Rachel Karchin, Laura A. Sena · 2024
Read Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer by Dena P. Rhinehart, Jiaying Lai, David E. Sanin, Varsha Vakkala, Adrianna Mendes, Christopher Bailey, Emmanuel S. Antonarakis, Channing J. Paller, Xiaojun Wu, Tamara L. Lotan, Rachel Karchin, Laura A. Sena (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11612198.txt.
Description
Rhinehart leads a large team reporting one prostate cancer case on resistance, in work from twenty twenty-four. Metastatic prostate cancer is not curable because it acquires therapy resistance. Resistance can come from changed sensitive cells or from outgrowth of a resistant subpopulation.
Direct proof of the second route in prostate patients was lacking. Their case report serves as proof of principle, tracing tumor heterogeneity inside one patient. Distinct cell populations within the tumor responded differently to therapy. The resistant population expanded under treatment pressure. Such case level tracking shows why biopsies of one site can mislead whole body treatment choices.
Catalog record
| CREATOR | Dena P. Rhinehart, Jiaying Lai, David E. Sanin, Varsha Vakkala, Adrianna Mendes, Christopher Bailey, Emmanuel S. Antonarakis, Channing J. Paller, Xiaojun Wu, Tamara L. Lotan, Rachel Karchin, Laura A. Sena |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |